Saronic Biotechnology

Executive Summary

Saronic Biotechnology is a private, early-stage biopharmaceutical company based in Cambridge, MA, focused on developing novel immunotherapies for hepatocellular carcinoma (HCC), the most common form of liver cancer. Founded in 2021 by physicians and research scientists with expertise in oncology, viral hepatitis, and immunology, the company aims to leverage these synergies to create curative treatments. Given its early stage, Saronic has not yet disclosed specific pipeline candidates, funding rounds, or valuation. The company's progress is closely tied to its ability to advance preclinical programs toward clinical development and secure partnerships or financing to support its research. With liver cancer representing a significant unmet need, Saronic's approach could offer a differentiated therapeutic option, though the company remains in a pre-clinical and pre-revenue phase, with limited public information available beyond its founding concept.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Data Readout for Lead Immunotherapy Candidate25% success
• H1 2027IND Filing or Regulatory Submission for First-in-Human Trial15% success
• 2026Series A or Seed Extension Financing Round40% success